The

Promise of

Interleukin-2

Therapy.

13-16 Nov. 2019

For autoimmune and inflammatory diseases, allergy, transplantation and cancer

Centre international de Conférences Sorbonne Université

4 place Jussieu - Patio 44-55

75005 - Paris, France

*To submit before the 15 sept. 2019

Confirmed Speakers

(by alphabetical order)

Abul K.  Abbas, Andre Ballesteros-Tato, Christophe Benoist, Jeffrey Bluestone, Jen Bon Lui, Onur Boyman, Michael Farrar, Garrison Fathman, Jason Fontenot, Agnes Hartemann, Jens Humrich, David Klatzmann, John Koreth, Vijay Kuchroo, Claude Le Pen, Zhanguo Li, Loui Madakamutil,  Thomas Malek, Encarnita Mariotti-Ferrandiz, Alexander Marson, Tewfik Miloud, Francisco Ramirez-Valle, Jerome Ritz, Michelle Rosenzwajg, Alberto Sanchez-Fueyo, Scott Snapper, Naomi Taylor, Nadia Tchao, Georges Tsokos, Harikesh Wong, Jonathan Zalevsky, Zinan Zhang

 

Friday 15th

9.00 am

Session III.b

Lessons from current clinical trials with plain IL-2

Chair : J. Koreth

 

1. IL-2 in T1D (A. Hartemann)

2. Low-dose IL-2 in chronic GVHD: lessons from 5 trials (J. Koreth)

3. IL-2 & liver transplantation (A. Sanchez-Fueyo)

10.30 - 11.00 am

Coffee Break

Session IV

From biomarkers to theranostics

Chair: C. Benoist

1. Systems Immunlog & drug development (C. Benoist) 

2. Effects of daily low dose IL-2 on Treg homeostasis (J. Ritz) 

3. Biomarkers of efficacy of IL-2 from clinical trials (M. Rosenzwajg)

4. TCRs as biomarkers (E. Mariotti-Ferrandiz) 

5. pSTAT5 as biomarkers (T. Miloud) 

1.00 pm

Lunch Break

2.00 pm

Session V.a

Novel IL-2s 

Chair : D. Klatzmann

 

1. AMG 592 is an Investigational IL-2 Mutein That Induces Highly Selective Expansion of Regulatory T Cells (N. Tchao)

2. NKTR-358: A polymer-conjugated IL-2 that drives the selective expansion of endogenous Tregs for the treatment of autoimmune diseases (C. Fanton)

 

3. Talks from abstracts

4.00 - 4.30 pm

Coffee Break

Session VI

IL-2 in cancer therapy 

Chair : J. Bluestone

 

1. Bempegaldesleukin: A polymer-conjugated IL-2 prodrug for multiple immune oncology applications (L. Madakamutil)

2. Selective IL-2 Immunotherapy to Fuel the Anti-Tumor Immune Response (D. Sahin)

3. Talks from abstracts

6.30 pm

End of the day

 

The Promise of Interleukin-2 Therapy.

13-16 Nov.

2019

13-16 Nov.

2019

Centre international de Conférences Sorbonne Université

4 place Jussieu - Patio 44-55

75005 - Paris, France